Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9418-9426

  Boswell, C Andrew ^a   Marik, Jan ^a   Elowson, Michael J ^a   Reyes, Noe A ^a   Ulufatu, Sheila ^a   Bumbaca, Daniela ^a   Yip, Victor ^a   Mundo, Eduardo E ^a   Majidy, Nicholas ^a   Van Hoy, Marjie ^a   Goriparthi, Saritha N ^a   Trias, Anthony ^a   Gill, Herman S ^a   Williams, Simon P ^a   Junutula, Jagath R ^a   Fielder, Paul J ^a   Khawli, Leslie A ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID I 123; 2 [2 [2 (4 HYDROXYPHENYL) N [2 [2 [4,7,10 TRIS[2 (TERT BUTOXY) 2 OXOETHYL] 1,4,7,10 TETRAAZACYCLODODECAN 1 YL]ACETAMIDO]ETHYL]ACETAMIDO]ACETAMIDO]ACETIC ACID I 125; 2,2',2'' [10 [14 (2,5 DIOXO 2,5 DIHYDRO 1H PYRROL 1 YL) 6 [2 (4 HYDROXYPHENYL)ACETYL] 2,8,11 TRIOXO 3,6,9,12 TETRAAZATETRADECYL] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIYL]TRIACETATE I 125; 2,2',2'' [10 [6 [2 (4 HYDROXYPHENYL)ACETYL] 2,8,11 TRIOXO 12 OXA 3,6,9 TRIAAZATETRADECYL] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7 TRIYL]TRIACETATE I 125; ANTIBODY; HALOGEN; INDIUM 111; IODINE 125; RADIOISOTOPE; TETRAXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; DRUG UPTAKE; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOCHEMISTRY; TUMOR XENOGRAFT; UGI REACTION;

EID: 84890527011     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401365h     Document Type: Article

References (38)

1. Wu, A. M.; Senter, P. D. Arming antibodies: prospects and challenges for immunoconjugates Nature Biotechnol. 2005, 23, 1137-1146
2. Davies, A. J. Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab Oncogene 2007, 26, 3614-3628
3. Boswell, C. A.; Brechbiel, M. W. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl. Med. Biol. 2007, 34, 757-778
4. 131I]SGMIB) Bioconjugate Chem. 2001, 12, 428-438
5. 131I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs Bioconjugate Chem. 2003, 14, 331-341
6. Vaidyanathan, G.; White, B. J.; Affleck, D. J.; Zhao, X. G.; Welsh, P. C.; McDougald, D.; Choi, J.; Zalutsky, M. R. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies Bioorg. Med. Chem. 2012, 20, 6929-6939
7. Boswell, C. A.; Bumbaca, D.; Fielder, P. J.; Khawli, L. A. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations AAAPS J. 2012, 14, 612-618
8. Wilbur, D. S. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling Bioconjugate Chem 1992, 3, 433-470
9. Nayak, T. K.; Brechbiel, M. W. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges Bioconjugate Chem. 2009, 20, 825-841
10. Shih, L. B.; Thorpe, S. R.; Griffiths, G. L.; Diril, H.; Ong, G. L.; Hansen, H. J.; Goldenberg, D. M.; Mattes, M. J. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels J. Nucl. Med. 1994, 35, 899-908
11. Perera, R. M.; Zoncu, R.; Johns, T. G.; Pypaert, M.; Lee, F. T.; Mellman, I.; Old, L. J.; Toomre, D. K.; Scott, A. M. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody Neoplasia 2007, 9, 1099-1110
12. 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo Cancer Res. 1995, 55, 5714s-5720s
13. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W. Antibody-targeted radiation cancer therapy Nature Rev. Drug Discovery 2004, 3, 488-499
14. Thorpe, S. R.; Baynes, J. W.; Chroneos, Z. C. The design and application of residualizing labels for studies of protein catabolism FASEB J. 1993, 7, 399-405
15. Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action Trends Pharmacol. Sci. 2009, 30, 356-362
16. Stein, R.; Govindan, S. V.; Mattes, M. J.; Chen, S.; Reed, L.; Newsome, G.; McBride, B. J.; Griffiths, G. L.; Hansen, H. J.; Goldenberg, D. M. Improved iodine radiolabels for monoclonal antibody therapy Cancer Res. 2003, 63, 111-118
17. Govindan, S. V.; Mattes, M. J.; Stein, R.; McBride, B. J.; Karacay, H.; Goldenberg, D. M.; Hansen, H. J.; Griffiths, G. L. Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing d -amino acids Bioconjugate Chem. 1999, 10, 231-240
18. Ugi, I.; Meyr, R.; Fetzer, U.; Steinbruckner, C. Versuche mit Isonitrilen Angew. Chem. 1959, 71, 386
19. Domling, A.; Ugi, I. I. Multicomponent Reactions with Isocyanides Angew. Chem., Int. Ed. Engl. 2000, 39, 3168-3210
20. Junutula, J. R. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nature Biotechnol. 2008, 26, 925-932
21. DeNardo, G. L.; DeNardo, S. J.; O'Donnell, R. T.; Kroger, L. A.; Kukis, D. L.; Meares, C. F.; Goldstein, D. S.; Shen, S. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma Clin. Lymphoma 2000, 1, 118-126
22. Sharkey, R. M.; Behr, T. M.; Mattes, M. J.; Stein, R.; Griffiths, G. L.; Shih, L. B.; Hansen, H. J.; Blumenthal, R. D.; Dunn, R. M.; Juweid, M. E.; Goldenberg, D. M. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22 Cancer Immunol. Immunother. 1997, 44, 179-188
23. Li, W. P.; Lewis, J. S.; Kim, J.; Bugaj, J. E.; Johnson, M. A.; Erion, J. L.; Anderson, C. J. DOTA- d -Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy Bioconjugate Chem. 2002, 13, 721-728
24. Tei, L.; Gugliotta, G.; Avedano, S.; Giovenzana, G. B.; Botta, M. Application of the Ugi four-component reaction to the synthesis of ditopic bifunctional chelating agents Org. Biomol. Chem. 2009, 7, 4406-4414
25. 125I]Iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies Int. J. Radiat. Appl. Instrum. B 1992, 19, 289-295
26. Shen, B. Q. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nature Biotechnol. 2012, 30, 184-189
27. Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Mochizuki, M.; Nakamura, H.; Sonoo, H. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 Br. J. Cancer 1999, 79, 707-717
28. Pastuskovas, C. V. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model Mol. Cancer Ther. 2012, 11, 752-762
29. 4DOTA): structural overview and analyses on structure-stability relationships Coord. Chem. Rev. 2009, 253, 1906-1925
30. Gnidehou, S.; Caillou, B.; Talbot, M.; Ohayon, R.; Kaniewski, J.; Noel-Hudson, M. S.; Morand, S.; Agnangji, D.; Sezan, A.; Courtin, F.; Virion, A.; Dupuy, C. Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site FASEB J. 2004, 18, 1574-1576
31. Auf Dem Brinke, D.; Hesch, R. D.; Kohrle, J. Re-examination of the subcellular localization of thyroxine 5′-deiodination in rat liver Biochem. J. 1979, 180, 273-279
32. 125I labeled N -succinimidyl p -iodobenzoate for use in radiolabeling antibodies Int. J. Radiat. Appl. Instrum. B 1989, 16, 727-733
33. Zalutsky, M. R.; Narula, A. S. Radiohalogenation of a monoclonal antibody using an N -succinimidyl 3-(tri- n -butylstannyl)benzoate intermediate Cancer Res. 1988, 48, 1446-1450
34. Stein, R.; Govindan, S. V.; Hayes, M.; Griffiths, G. L.; Hansen, H. J.; Horak, I. D.; Goldenberg, D. M. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody Clin. Cancer Res. 2005, 11, 2727-2734
35. Behr, T. M.; Sharkey, R. M.; Juweid, M. E.; Blumenthal, R. D.; Dunn, R. M.; Griffiths, G. L.; Bair, H.-J.; Wolf, F. G.; Becker, W. S.; Goldenberg, D. M. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives Cancer Res. 1995, 55, 3825-3834
36. Boswell, C. A.; Ferl, G. Z.; Mundo, E. E.; Schweiger, M. G.; Marik, J.; Reich, M. P.; Theil, F. P.; Fielder, P. J.; Khawli, L. A. Development and evaluation of a novel method for preclinical measurement of tissue vascular volume Mol. Pharmaceutics 2010, 7, 1848-1857
37. Boswell, C. A. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats Bioconjugate Chem. 2011, 22, 1994-2004
38. Boswell, C. A. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2 Br. J. Pharmacol. 2013, 168, 445-457